Skip to content

Eosinophilia Diagnosis

Algorithm for the Early Diagnosis and Treatment of Patients With Eosinophilia

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02581514
Acronym
EOSINOPHILIM
Enrollment
53
Registered
2015-10-21
Start date
2015-10-01
Completion date
2021-05-03
Last updated
2026-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypereosinophilic Syndrome

Keywords

decision algorithm

Brief summary

Eosinophilia, defined by a blood eosinophil granulocytes rate greater than 500 / mm3, is frequently encountered in internal medicine. Its causes are varied: atopy, drug allergies, parasitic infections, autoimmune diseases and solid neoplasias. Over 200 etiologies have been reported, some difficult to diagnose and can be life-threatening Eosinophilia can be a diagnostic dilemma, as the etiologies are extensive and varied. The aim of this study is to assess the feasibility of a diagnostic approach based on a decision algorithm in a group of patients with eosinophilia. We assume that a procedure with a hierarchy of additional tests would increase the frequency of diagnosed cases while decreasing the time to diagnosis. This procedure defined by an algorithm would even reduce the number of tests necessary to reach a diagnosis.

Detailed description

Eosinophilia, defined by a blood eosinophil granulocytes rate greater than 500 / mm3, is frequently encountered in internal medicine. Its causes are varied: atopy, drug allergies, parasitic infections, autoimmune diseases and solid neoplasias. Over 200 etiologies have been reported, some difficult to diagnose and can be life-threatening Eosinophilia can be a diagnostic dilemma, as the etiologies are extensive and varied. The aim of this study is to assess the feasibility of a diagnostic approach based on a decision algorithm in a group of patients with eosinophilia. The contribution to the diagnosis of a hierarchical strategy for prescribing additional tests , based on clinical examination as well as some simple diagnostic tests, has never been evaluated We assume that a procedure with a hierarchy of additional tests would increase the frequency of diagnosed cases while decreasing the time to diagnosis. This procedure defined by an algorithm would even reduce the number of tests necessary to reach a diagnosis. All types of patients are tacked into account: those coming from the university hospital, referred by general practitioners or by other hospitals. In addition we address the internal medicine patients ,but also those of Hematology and Infectious Diseases. A comparison of these various groups would be relevant, since disorders that may be different. Once enrolled, the patient is drived by the investigator through the various steps and exams imposed by the algorithm. Indeed, during 5 months (Day1 5, 43, 71 , 85 , 99 ,113 and month 5), patient is asked to comply to the various exams and assessment imposed by the algorithm and that should lead to a diagnosis

Interventions

OTHERScheduled exams and diagnosis

Scheduled exams and diagnosis circuit as imposed by the algorithm

Sponsors

University Hospital, Limoges
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patient having one of the three following criteria: * hypereosinophilia\> 1500 / mm3, checked on at least two samples (interval between 2 samples at the discretion of the clinician) * or hypereosinophilia\> 500 cells / mm3 and organ damage with infiltration NCB proven by pathological examination, * or hypereosinophilia\> 500 cells / mm3 and found consistently for at least six months (present on all controls carried out before inclusion). 2. Patient affiliated or beneficiary of a social security system 3. Patient who signed the informed consent

Exclusion criteria

1. Patient with solid tumors known (under chemotherapy or planned) 2. Patient unable to understand or to adhere to the Protocol 3. Patient unable to give consent 4. Pregnant or breastfeeding women 5. Patient already participating in an interventional trial

Design outcomes

Primary

MeasureTime frameDescription
Number of patients having correctly follow the diagnosis algorithm5 monthsThis outcome measure how many patients have correctly followed the diagnosis algorithm

Secondary

MeasureTime frameDescription
Rate of diagnosis5 monthsEvaluate the rate of diagnosis using our diagnosis algorithm
Assess the time to diagnosis5 monthsAssess the time to diagnosis
Description of diagnosis5 monthsTo compare the diagnosis found in our study to the published cohort.

Countries

France

Contacts

PRINCIPAL_INVESTIGATORHoly BEZANAHARY

University Hospital, Limoges

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 25, 2026